At the Academy of Managed Care Pharmacy (AMCP) annual meeting last week, several posters bolstered existing real-world evidence that biosimilar adalimumab was associated with similar outcomes to those of Humira, and that may translate into the absence of any significant nocebo effect. Only 2% Switched Back to Humira Researchers from Employers Health, Columbus, Ohio,1 evaluated … Continue reading Good Outcomes, Little Nocebo Effect With Adalimumab Biosimilars